CytoSorbents Corporation — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018. The filing is an annual report, not a standalone quarterly filing; selected unaudited fourth-quarter results are also summarized below. Filed March 7, 2019.
Business context
CytoSorbents develops and commercializes blood-purification devices based on porous polymer adsorbents. Its lead product, CytoSorb, is CE-marked in the EU and sold internationally for cytokine removal, including critical-care and cardiac-surgery uses; 2018 EU label extensions added bilirubin removal for liver disease and myoglobin removal in trauma. CytoSorb is not approved for sale in the United States. The company reported more than 56,000 human treatments and commercial presence through direct sales or partners in 55 countries. Other products are primarily in development; VetResQ is marketed for U.S. veterinary use.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 | Change / context |
|---|---|---|---|
| Total revenue | $22.50 million | $15.15 million | Up 49% |
| Product sales | $20.25 million | $13.38 million | Up 51%; principally CytoSorb |
| Grant income | $2.25 million | $1.77 million | Up 27% |
| Gross profit | $15.01 million | $9.63 million | Up 56% |
| Product gross margin | Approximately 74% | Approximately 71% | Improved manufacturing efficiency and, to a lesser extent, currency effects |
| Operating expenses | $30.60 million | $19.47 million | Up 57%; R&D and SG&A increased materially |
| Operating loss | $(15.58) million | $(9.84) million | Loss widened |
| Net loss | $(17.21) million | $(8.46) million | 2017 common-stockholder loss was $(8.80) million after a warrant-related dividend |
| Net loss per share, basic and diluted | $(0.56) | $(0.32) | Loss per share increased |
Fourth quarter 2018: Revenue was $6.08 million, gross margin dollars were $4.00 million, operating loss was $(5.59) million, and net loss attributable to common stockholders was $(5.40) million, or $(0.17) per share. Fourth-quarter 2017 revenue was $4.65 million and common-stockholder net loss was $(3.15) million.
- Cash flow: Net cash used in operating activities was $10.84 million in 2018, compared with $6.46 million in 2017. Investing activities used $1.52 million; financing activities provided $17.47 million.
- Cash and liquidity: Year-end cash and cash equivalents were $22.37 million, up from $17.32 million. Current assets were $28.26 million, current liabilities $6.54 million, and working capital $21.73 million.
- Debt: Term-loan principal was $10.0 million at year-end; carrying value was $9.94 million before current/noncurrent presentation. The loan bears interest at prime plus 3.66% (9.16% at year-end) and is due April 1, 2022. An additional $5 million tranche was available subject to conditions through March 31, 2019.
- Funding and dilution: 2018 at-the-market stock sales generated approximately $14.13 million net proceeds from 1.52 million shares. Shares outstanding were 31.77 million at year-end; the filing reports 31.86 million outstanding as of February 28, 2019.
Material changes versus 2017
- Product sales growth and improved product gross margin lifted gross profit, but operating expenses rose substantially. R&D expense increased 140% to $7.72 million, largely reflecting REFRESH 2-AKI trial costs; SG&A increased 40% to $20.87 million.
- Net interest expense rose to $1.46 million, including a $637,000 Bridge Bank success fee settled in shares. Foreign-currency transactions shifted from a $1.45 million gain in 2017 to a $785,000 loss in 2018.
- The expanded New Jersey manufacturing facility began production in 2018 and was described as providing four times prior capacity. Management expects this expansion to support demand and improve margins over time.
- The company expanded CytoSorb’s EU label and revised the Fresenius arrangement: guaranteed minimum quarterly purchases and payments were removed for 2019, and certain territories moved to co-marketing. New Fresenius distribution agreements covered South Korea and Mexico, subject to regulatory registration.
Outlook, risks, and unusual items
- Management said available cash was expected to fund operations into 2020, but anticipated needing additional capital. The auditor’s report and financial-statement note state that substantial doubt exists about the company’s ability to continue as a going concern; the statements include no adjustments for the outcome of this uncertainty.
- Management planned to complete enrollment in the U.S. REFRESH 2-AKI cardiac-surgery trial by 2020, subject to possible delays, and to seek PMA approval in 2021 if the study succeeds. As of March 6, 2019, 56 patients had enrolled. The company-funded/partner-supported German REMOVE trial had enrolled 130 patients as of February 28, 2019; an interim review recommended continuation and reported no device-associated adverse events in treated patients.
- Commercial growth depends on adoption, repeat use, reimbursement, distributor execution, and registrations in individual markets. Germany remains a major sales market; product revenue is concentrated internationally and exposed to foreign-exchange movements.
- CytoSorb’s U.S. approval and clinical effectiveness are uncertain. The filing notes that earlier sepsis studies were limited and not powered to establish mortality benefit; the REFRESH I study was not powered to assess clinical outcomes. Most pipeline products are unapproved and require further development and regulatory review.
- Other material risks include continuing losses, financing needs and potential shareholder dilution, manufacturing scale-up, competition, patent protection, product liability, and dependence on key personnel. The employment agreements for the CEO, CFO, and COO had expired at year-end 2018; negotiations for new agreements were ongoing.
- Royalties and license fees include a 3% royalty on specified CytoSorb revenues to an investor and 2.5%–5% royalties on specified product sales under the Purolite settlement/license arrangement. The company recorded about $600,000 and $1.00 million, respectively, in 2018.
Most important facts for investors to verify
- Whether sales growth, repeat orders, and product gross-margin improvement continued after 2018, and the extent of Germany’s contribution.
- Current cash runway, operating cash burn, financing needs, and any subsequent equity issuance or debt draw; reconcile management’s stated cash-burn estimate with reported 2018 operating cash use of $10.84 million.
- REFRESH 2-AKI enrollment pace, trial cost, timing, and eventual primary endpoint results; distinguish mechanistic or safety observations from demonstrated clinical benefit.
- Whether the Fresenius territory changes and removal of 2019 minimum-purchase commitments affect partner sales, and whether Korea and Mexico registrations and launches progress.
- Reimbursement status and realized hospital adoption in key markets, alongside product liability, regulatory, patent, and foreign-exchange exposures.